Stock 506197 BLISS GVS PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Bliss GVS Pharma Limited Stock

Equities

506197

INE416D01022

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:49 2024-04-18 am EDT 		5-day change 1st Jan Change
110.8 INR -1.16% Intraday chart for Bliss GVS Pharma Limited -3.48% -11.04%
Jan. 23 Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Financials

Sales 2022 7.47B 89.5M Sales 2023 7.52B 90M Capitalization 7.42B 88.86M
Net income 2022 150M 1.8M Net income 2023 709M 8.49M EV / Sales 2022 1.03 x
Net cash position 2022 256M 3.06M Net Debt 2023 335M 4.02M EV / Sales 2023 1.03 x
P/E ratio 2022
53.8 x
P/E ratio 2023
10.6 x
Employees 763
Yield 2022
0.65%
Yield 2023
0.7%
Free-Float 34.66%
More Fundamentals * Assessed data

Chart Bliss GVS Pharma Limited

Dynamic Chart

Latest news about Bliss GVS Pharma Limited

Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Assistant Commission of State Tax Maharashtra, Mumbai Initiates Search At Certain Premises of Bliss GVS Pharma Limited CI
Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Gets Establishment Inspection Report from US FDA for Palghar, India Unit MT
Bliss Gvs Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable MT
Bliss GVS Pharma Gets Three Observations from US FDA's Plant Inspection in Maharashtra, India MT
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bliss GVS Pharma Names New CFO MT
Bliss GVS Pharma Limited Appoints Mr. Deepak Sawant as Chief Financial Officer CI
More news

Analyst Recommendations on Bliss GVS Pharma Limited

Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable MT
Infomerics Raises Rating on Bliss GVS Pharma's Long-Term Bank Financing to BBB; Outlook Lowered to Stable MT
More recommendations

Press releases Bliss GVS Pharma Limited

Bliss GVS Pharma Presents Gh?150,000 Anti-Malaria Drugs to Hospitals AQ
More press releases

Quotes and Performance

1 day-1.16%
1 week-3.48%
Current month-1.60%
1 month+1.37%
3 months-12.79%
6 months+24.03%
Current year-11.04%
More quotes

Highs and lows

1 week
108.00
Extreme 108
113.55
1 month
101.65
Extreme 101.65
121.00
Current year
100.55
Extreme 100.55
142.15
1 year
71.00
Extreme 71
148.95
3 years
66.25
Extreme 66.25
148.95
5 years
66.25
Extreme 66.25
224.00
10 years
39.50
Extreme 39.5
230.00
More quotes

Managers and Directors - Bliss GVS Pharma Limited

Managers TitleAgeSince
Gagan Harsh Sharma CEO
 Chief Executive Officer 41 21-01-20
Deepak Sawant DFI
 Director of Finance/CFO 44 22-12-29
Aditi Himanshu Bhatt CMP
 Compliance Officer - 15-11-08
Members of the board TitleAgeSince
Subramanian R. Vaidya CHM
 Chairman 81 11-07-31
Vibha Gagan Sharma BRD
 Director/Board Member 40 08-07-28
Shruti Vishal Rao BRD
 Director/Board Member 39 06-07-26
More insiders

Quotes

Date Price Change Volume
24-04-18 110.8 -1.16% 37,025
24-04-16 112.2 +1.82% 16,281
24-04-15 110.2 -1.48% 44,874
24-04-12 111.8 -2.66% 45,472
24-04-10 114.8 -0.17% 38,725

Delayed Quote Bombay S.E., April 18, 2024 at 06:00 am EDT

More quotes

Company Profile

Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Sector
Pharmaceuticals
Calendar
2024-05-16 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
BLISS GVS PHARMA LIMITED Stock Bliss GVS Pharma Limited
-11.04% 140M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.40% 44.1B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+17.11% 21.97B
CIPLA LIMITED Stock Cipla Limited
+8.10% 13.27B
SANDOZ GROUP AG Stock Sandoz Group AG
+6.06% 13.22B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+35.95% 11.36B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.53% 7.07B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+7.71% 5.23B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 506197 Stock